Trial
NCT04412707
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Oncopeptides AB
Collaborators
—
Condition
RRMM
Intervention
Melphalan
Why stopped
The sponsor decided to terminate the study following an FDA request of a partial clinical hold.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-09